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Abstract
Background and aim: Resection of colorectal liver metastases has become a standard of care, although the value of this
procedure in non-colorectal non-neuroendocrine (NCRNNE) metastases remains controversial and is still a matter of
debate. The aim of the study was to determine the utility of liver resection in the long-term outcome of patients with
NCRNNE metastases. Material and methods: The records of 106 patients who underwent liver resection for NCRNNE
metastases in the period 1989 to 2006 at 5 HPB Centers in Argentina were analyzed. Patient demographics, tumor
characteristics, type of resection, long-term outcome and prognostic factors were analyzed. Depending on primary tumor
sites, a comparative analysis of survival was performed. Results: Mean age was 54 (1776). Hepatic metastases were solitary
in 62.3% and unilateral in 85.6%. Primary tumor sites: Urogenital (37.7%), sarcomas (21.7%), breast (17.9%),
gastrointestinal (6.6%), melanoma (5.7%), and others (10.4%). Fifty-one major hepatectomies and 55 minor resections
were performed. Twenty patients underwent synchronous resections. An R0 resection could be achieved in 89.6%.
Perioperative mortality was 1.8%. Overall, 1-year, 3-year, and 5-year survival rates were 67%, 34%, and 19%, respectively.
Survival was significantly longer for metastases of urogenital (p0.0001) and breast (p0.003) origin. Curative resections
(p0.04) and metachronous disease (p0.0001) were predictors of better survival. Conclusions: Liver resection is an
effective treatment for NCRNNE liver metastases; it gives satisfactory long-term survival especially in metachronous
disease, in patients with metastases from urogenital and breast tumors and when R0 procedures can be performed.
Introduction
Resection of colorectal liver metastases has become a
standard of care, with 5-year survival rates from 42%
to 71% reported in solitary metastases [1]. A benefit
from resection has also been demonstrated in patients
with liver metastases from neuroendocrine tumors,
with a reduced incidence of disease-related symptoms
and an extended median patient survival from 61% to
76% at 5 years [2]. However, the efficacy of resection
in patients with non-colorectal non-neuroendocrine
(NCRNNE) liver metastases remains unclear. Main
factors are: heterogeneity of the primary tumor types
and its biological behavior, the limited number of
patients reported in each study, the frequent inclusion
of patients with neuroendocrine or unknown primary
tumors, and the absence of prospective studies.
Our study was designed to determine the utility of
liver resection in the long-term outcome of patients
with NCRNNE liver metastases treated at five hepa-
topancreatobiliary (HPB) centers in Argentina.
Material and methods
The records of 106 patients who underwent liver
resection for NCRNNE liver metastases from 1989 to
2006 at 5 HPB centers in Argentina were analyzed.
Patients with direct invasion of the liver by the
primary tumor or by peritoneal implants, and patients
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with liver metastases from unknown primary tumors
were excluded. Liver metastases diagnosed along with
the primary tumor were defined as synchronous, and
the time frame to define a metachronous metastase
was at least 2 months after completion of treatment of
the primary tumor. Major hepatic resection was
defined as resection of three or more segments, while
a curative resection (R0) was defined as complete
removal of any clinically evident tumor lesion(s) with
negative pathological margins. Any infiltration of the
resection margin with tumor cells in the histological
specimen was defined as R1 resection. Operative
mortality included any death attributed to liver
resection and all deaths within 30 days of partial
hepatectomy. Patient demographics, tumor character-
istics, type of resection, long-term outcome, and
prognostic factors were analyzed. For statistical ana-
lysis, and depending on the primary tumor origin,
patients were grouped within the following categories:
genitourinary, gastrointestinal, breast, sarcomas, mel-
anoma and others.
The following factors were assessed specifically as
prognostic factors: age, disease-free interval from
resection of the primary tumor to discovery of liver
metastases, primary tumor origin, synchronous vs
metachronous presentation, number of liver metas-
tases, intrahepatic distribution (unilobar vs bilobar),
type of liver resection (minor vs major), and resection
margin (R0 vs R1).
An analysis was performed in accordance with the
risk model for patients with NCRNNE liver metas-
tases developed by Adam et al. [3].
Statistical analysis
Qualitative variables expressed as frequencies and
percentages were compared using the chi-square test.
For quantitative variables expressed as mean values
and standard deviation, comparison was done by
applying Student’s t-test. The Kaplan-Meier method
was used to calculate actuarial survival rates, and
intergroup comparisons were performed by means of
the log-rank test. Variables found to be significant by
univariate analysis were assessed by multivariate ana-
lysis using a Cox regression. Statistical significance was
considered to exist when pB0.05. Statistical analyses
were performed using the SPSS software v. 12.0 (SPSS
Inc., Chicago, Ill., USA).
Results
A total of 106 patients were identified as undergoing
hepatic resection for NCRNNE metastases. The
median age was 54 years (range 17 to 76 years),
with a male:female ratio of 1:1.3 (45:61). Twenty-
three percent of the patients presented with synchro-
nous lesions, whereas 77% had metachronous lesions.
The median disease-free interval after primary treat-
ment in all patients was 29 months, and in the 83
patients presenting with metachronous disease this
was 40 months. The primary tumor origins are
described in Table I. Most common sites in the
genitourinary group were renal and ovarian. Stomach
and pancreas were most important in the gastroin-
testinal group and other relevant primary sites were
breast and sarcomas. The melanoma group included
4 patients with choroid melanoma and 2 with
cutaneous melanoma. Depending on primary tumor
origin, the median disease-free interval after primary
treatment was 14 months in gastrointestinal tumors,
29 months in sarcoma, 37 months in melanoma, 38
months in genitourinary, 46 months in others, and 75
months in breast tumors. After treatment of the
primary tumor, 47 patients (44%) received chemo-
therapy and/or radiotherapy (84% in breast tumors
and 35% in genitourinary tumors).
Diagnostic imaging was not standardized over the
study period because of the duration of the study and
the evolution of imaging modalities. However, ultra-
sonography and computed tomography were used in
95% of the patients. Other imaging modalities were
magnetic resonance imaging in 14% and positron
emission tomography (PET) scanning in 5.7%.
A percutaneous biopsy was performed in 8 patients
(7.5%).
At the time of hepatic resection, 66 (62.3%)
patients had a single lesion and 91 (85.8%) unilateral
liver involvement (right or left hemiliver). Major
hepatic resection was required in 51 (48.1%). A
synchronous resection of the liver and the primary
tumor was performed in 20 (18.8%) patients (8
sarcomas, 6 genitourinary, 3 gastrointestinal, 2 mel-
anomas and 1 suprarenal). Ninety-five (89.6%) pa-
tients underwent complete (R0) resection of the
tumor and 11 (10.3%) had microscopic residual
disease (R1). A second liver resection was performed
in 5 patients (4.7%) and the other 6 were treated by
Table I. Primary tumor origin in 106 patients with NCRNNE
metastases.
Genitourinary 40 (37.7%)
Renal 21
Ovarian 14
Testicular 3
Uterine 1
Bladder 1
Sarcomas 23 (21.7%)
Breast 19 (17.9%)
Gastrointestinal 7 (6.6%)
Stomach 3
Pancreas 3
Duodenum 1
Melanoma 6 (5.7%)
Others 11 (10.4%)
Pulmonary 3
Neck 2
Adrenal 2
Miscellaneous 4
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chemotherapy because of unresectable disease. Peri-
operative mortality occurred in two (1.8%) patients:
sepsis (1) and liver failure (1) were the main causes.
Outcome
The median follow-up time was 28 months and 5
patients were lost to follow-up. Overall, 1, 3, and 5-
year survival rates were 67%, 34%, and 19%, respec-
tively, with a median overall survival of 27 months
(Figure 1). Depending on primary tumor origin, 5-
year survival was 53% for breast origin, 30% for
genitourinary, and 12% for other tumors, i.e. princi-
pally related to neck sites (larynx, submaxilar). In the
sarcoma group, only 1 patient is alive at 46 months
and there were no 5-year survivors from the gastro-
intestinal and melanoma groups (Figure 2).
The univariate and multivariate analyses of prog-
nostic factors demonstrated that the origin of the
primary tumor, the metachronous metastases presen-
tation, and the curative resections (R0) were impor-
tant predictors of long-term survival (Table II). Age,
disease-free interval, number of metastases, unilateral
versus bilateral disease, and type of liver resection did
not affect prognosis.
In accordance with the risk model for patients with
NCRNNE liver metastases developed by Adam et al.,
patients were grouped into three categories (low-risk
03 points, mid-risk 46 points, and high risk6
points) [3]. Our study showed no 5-year survival in
the high-risk patients, only 8% in the mid-risk, and
31% in the low-risk group (Figure 3).
Discussion
The benefits of surgical resection have been well
documented in patients with metastases from color-
ectal and neuroendocrine tumors [2]. However, its
role in NCRNNE metastases remains controversial.
Previous studies have reported single-center experi-
ences with a wide variety of primary tumor types
distributed in a small number of patients [47]. In
order to overcome the limitations of single-center
reports we designed a study to analyze data from five
referral HPB centers from Argentina.
Average age in the fifth decade and predominance
of the female population in our study were common
features to those in previous reports (Table III). Only
3 single centers and 1 multicenter study had already
reported data from more than 100 patients with
resection of NCRNNE metastases. In general, the
time intervals of the different studies ranged from 10
to 23 years [5,8]. In respect of exclusion criteria,
although 7 out of 11 previous studies included
patients with metastases from unknown primary
tumors, we excluded these studies in order to avoid
bias in the outcome analysis of the miscellaneous
groups [24,812]. Furthermore, as already demon-
strated, metastases from neuroendocrine tumors
should be analyzed separately considering this is a
unique group with better prognosis [3].
In the past decade, liver resection has become a
fairly common therapeutic option for patients with
Figure 1. Overall survival of patients who underwent liver resection
for NCRNNE metastases (n106).
Figure 2. Comparison of survival depending on primary tumor
origin.
Table II. Analysis of prognostic factors for survival after resection
for NCRNNE liver metastases.
Prognostic factor
Univariate
(p)
Multivariate
(p)
Age B30 year, 30 year, 60
year
NS NS
Presentation (metachronous vs
synchronous)
0.0001 0.001
Disease-free interval B24 m,
24 m
NS NS
Origin of primary tumor
Breast 0.003 0.03
Genitourinary 0.0001 0.001
No. of metastases (solitary vs
multiple)
NS NS
Distribution (unilateral vs bilateral) NS NS
Type of liver resection (minor vs
major)
NS NS
Curative resection (R0) 0.04 0.01
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NCRNNE metastases because mortality with this
procedure has declined as a result of better preopera-
tive imaging, patient selection, anesthetic, and critical
care management and understanding of liver anat-
omy. Analyzing the present series along with 11 other
series reported in the literature indicates that major
resections were generally performed from 17% to
67% and perioperative mortality ranged from 0 to 4%
[2,4,5].
The decision to proceed with liver resection in a
patient with NCRNNE metastases must come after
thorough evaluation. PET will have a progressively
critical role in the selection of patients for surgery
improving the preoperative staging of the disease [2].
Staging laparoscopy could also be a useful tool in
patient selection. In a study by D’Angelica et al., 20%
of the patients with potentially resectable NCRNNE
metastases, and who underwent a staging laparo-
scopy, were spared a non-therapeutic laparotomy,
and two-thirds of them with unresectable disease
were identified in this procedure [13].
Patients with NCRNNE metastases conform with a
heterogeneous group with different anatomic factors
and distinct primary tumor biology. As an example,
liver metastasis in non-gastrointestinal cancer, by
definition, indicates systemic tumor spread. Selection
of patients with favorable tumor biology is the key
point in defining which patients will benefit most from
liver resection. Several studies have demonstrated that
long-term survival can be achieved in a subset of
patients with NCRNNE metastases (Table III). It is
important to identify the prognostic factors predictive
of more favorable outcomes after liver resection for
attempted cure. In our data, primary tumor origin,
metachronous metastases, and curative resections
were independent prognostic factors of long-term
survival. Primary tumor type is the most common
prognostic factor described, and favorable survivals
are generally reported for genitourinary, breast, and
soft tissue sites [3,7,12,14]. In the present study,
genitourinary origin demonstrated a 30% 5-year
survival compatible with previous reports
[7,12,14,15]. Weitz et al. have recently shown a better
free relapse survival for reproductive versus non-
reproductive tract tumors [12]. Breast tumors, too,
have been considered a favorable group for resection
of liver metastases, with 5-year survival rates ranging
from 27% to 51% [16]. In our series, the highest
survival for breast tumors (53% at 5 years) could be
explained by the long median disease-free interval (78
months) presented in this group of patients compared
to other primary tumor origins. However, no con-
sensus has been demonstrated in this topic in previous
studies [17,18]. As far as sarcoma and other soft
tissue tumors are concerned, better outcomes have
been presented by other authors [3,9,10]. This could
be explained in our data by the high number of
patients who underwent synchronous resection of the
primary tumor and the metastases in the sarcoma
group 8/23 (34.7%)  a parameter that was associated
with poorer long-term survival. The worst outcome
was generally reported for metastases from gastro-
intestinal tumors [6,14,15,19,20].
Table III. Major studies on results of hepatectomy for NCRNNE liver metastases.
First author Year n Median age UPT NE
Major
resection
Perioperative
mortality% R0
Overall
5-year survival%
Elias [10] 1998 147 56 3 18%  2 75% 36
Hemming [4] 2000 37 56 3  62% 0 89% 45
Benevento [5] 2000 18 54  22% 17% 0  21
Laurent [7] 2001 39 55   51% 0  35
Yedibela [8] 2005 162 60 10 9% 38% 1 72% 26
Ercolani [14] 2005 83 54   41% 0  34
Cordera [11] 2005 64 56 3  59% 1.5 88% 30
Weitz [12] 2005 141 55 5  48% 0 96% 57 (3-year)
Adam [3] 2006 1452 53 29  55% 2.3 83% 36
Earle [20] 2006 95 58  19% 41% 2.1 88% 35
Reddy [2] 2006 82 52 2 9% 52% 4 79% 37
Lendoire 2007 106 54   48% 1.8 90% 19
UPTnumber of patients with unknown primary tumors; NEnumber of patients with neuroendocrine tumors.
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Figure 3. Comparison of survival according to risk score described
by Adam et al. [3].
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The disease-free interval between treatment of the
primary tumor and development of liver metastases is
viewed as a marker for tumor biology. The notion of a
longer disease-free interval possibly being associated
with less aggressive tumor biology is supported by
studies demonstrating longer survival in patients with
disease-free intervals more than 12 or 24 months
[2,7,9,11,12,20]. Metastases with short disease-free
intervals could be associated with advance stages of
the disease and worse prognosis. Our study did not
show significant differences and this is probably
related to the discrepancy between the disease-free
intervals in the groups analyzed (14 months in
gastrointestinal tumors to 75 months in breast tu-
mors). As shown previously by others, only patients
with synchronous presentation of the primary tumor
and the metastases demonstrated a significant reduc-
tion in overall survival [11,20].
The third relevant prognostic factor in our study
was the likelihood of performing a microscopically
complete tumor resection, which was achieved in 90%
of the patients. Other studies have reported R0
resections in the range 72% to 96% [8,9] (Table III).
In a recently published multicenter study, Adam
et al. analyzed 1452 patients with hepatic resection for
NCRNNE liver metastases and developed a prognos-
tic model [3]. The prognostic factors considered in
the risk model were based on patient, tumor, and
hepatectomy characteristics. Application of the risk
model in our study showed 5-year survival within the
range demonstrated by Adam et al. [3]. Only the mid-
risk group presented a lower survival.
In conclusion, this report indicates that liver resec-
tion is an effective treatment for NCRNNE liver
metastasis. Long-term survival after liver resection is
satisfactory, especially in patients with metachronous
disease, in patients with metastases from genitour-
inary and breast tumors, and when a curative resec-
tion can be performed. Analysis of our data using the
risk model developed by Adam et al. [3] demonstrated
a clear benefit of resection in the low-risk group of
patients. Improvement in preoperative staging and
progressive application of development of new multi-
modality treatments will be the key to improved
survival in this disease.
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